Agios Pharmaceuticals, Inc. (AGIO): what the price assumes

In the published model solve dated 2026-Q2, anchored at $31.72, Agios Pharmaceuticals, Inc. (AGIO) is priced for today's economics sustained for ~13.6 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/AGIO

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.2 years.

Reconcile: at the x-ray's 9.3% required return this reads ~10.2 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Mitapivat is now selling under two brand names in two diseases, and U.S. net product revenue more than doubled to $18.8 million in the first quarter of 2026 from $8.7 million a year earlier on the late-January launch of AQVESME in thalassemia.
• The single largest dated event ahead is the FDA decision on mitapivat in sickle cell disease, which carries a goal date of November 1, 2026 under Priority Review.
• The cost of the attempt is the risk: the company runs an operating loss of roughly $460 million against about $55 million of trailing revenue, and on July 21, 2026 it stopped developing tebapivat in sickle cell disease after Phase 2 data.

Bull Case

One of the standard ways of valuing a company returns nothing at all for Agios. A discounted cash-flow model needs cash flow, and Agios generates the opposite, so the calculation floors out at zero. Every other approach lands below today's price too: measured against book value the price is roughly double, and measured against what similar companies fetch per dollar of sales it is many times higher. A reader could stop there and conclude the stock is expensive on every reasonable measure, which would be accurate and would also miss what is being bought. These approaches all read backwards from a profit-and-loss statement whose largest line is the cost of trying to prove that a molecule works in a second, third and fourth disease. They are measuring the expense of the attempt, not the value of succeeding.

What succeeding looks like is already partly visible. Mitapivat, an oral pill that activates a specific enzyme in red blood cells, was approved first for pyruvate kinase deficiency and sold as PYRUKYND. In late January 2026 the same molecule launched in thalassemia under the name AQVESME, and U.S. net product revenue for mitapivat rose to $18.8 million in the first quarter from $8.7 million a year earlier, with 242 prescriptions written by certified physicians in the first two months of the launch. The economics of that revenue are what make the ramp matter: gross margin runs around 88%, which is normal for a small-molecule rare disease drug and means each incremental prescription is close to pure contribution. The commercial infrastructure is already paid for. The company built it, in its own words, to support the commercialization of PYRUKYND® in adult PK deficiency in the United States and has since expanded it.

The third indication is the one that changes the arithmetic. The FDA accepted a supplemental application for accelerated approval of mitapivat in sickle cell disease under Priority Review with a decision date of November 1, 2026. Pyruvate kinase deficiency affects a few thousand people. Sickle cell disease affects roughly a hundred times more. The Phase 3 data behind the filing was presented at a plenary session of the European Hematology Association meeting in 2026, which is where hematology puts the results it considers most consequential.

The balance sheet funds the wait without a lender in the room. Agios ended the first quarter of 2026 with $1.0 billion in cash, cash equivalents and marketable securities, and carries no funded borrowings against it. It got there in an unusual way: in August 2024 it sold the royalty on vorasidenib, a brain cancer drug it discovered and licensed out, to Royalty Pharma, which acquired 100 % of the Vorasidenib Royalty Rights payments made by Servier on account of up to $ 1.0 billion in U.S. net sales for each calendar year. That transaction turned a discovery Agios was never going to commercialize itself into the capital funding the programs it will. Dilution has been minimal as a result, with the share count up only about 1.9% a year over four years, which for a company at this stage of development is close to remarkable. Most of the peer group has funded itself by repeatedly selling stock; Agios funded itself by selling a royalty.

Bear Case

Start with what management has done with the money, because that is the clearest read available on how this company allocates capital. Agios discovered vorasidenib, licensed it to Servier, and then in August 2024 sold the royalty stream to Royalty Pharma for cash. That single transaction produced net income for the year ended December 31, 2024 of $673.7 million, against a net loss of $352.1 million in 2023 and $412.8 million in 2025. Read those three numbers in order and the shape of the business is unmistakable. One year of accounting profit came from selling an asset. The years either side of it are the actual operating reality, and the proceeds are now being spent at a rate of roughly $400 million a year on programs whose outcomes nobody can predict.

The most recent evidence of what that spending buys arrived four days ago. On July 21, 2026 the company reported that its Phase 2 trial of tebapivat in sickle cell disease did not demonstrate the level of differentiation required to support continued development, and discontinued the program. Hemoglobin responses were in line with the class and the safety profile held; the drug simply was not better enough to be worth continuing. That is a rational decision and it is also a write-off of years of spending. It happened in a program the company was funding out of the vorasidenib proceeds, and the pipeline still carries candidates in phenylketonuria and polycythemia vera at earlier stages, where the same outcome is available.

Against the loss-making biotech cohort, Agios spends unusually hard for what it takes in. Its operating loss runs at about eight and a half times its revenue, which places it near the bottom of a group where Editas runs at roughly three times revenue, Nektar at about two and a half, Kestra Medical at under one and a half, and Viridian at about five and a half. Only Recursion, at close to nine times, burns at a heavier ratio. High spending is defensible when it is buying a large indication, which is exactly the argument for the sickle cell program. It is much harder to defend across three or four simultaneous shots, which is what the current cost structure represents.

Now the price. At roughly thirty-eight times revenue, the market is assuming Agios eventually earns an operating margin around 35% and grows revenue at the fastest pace it can fund internally for something like two decades. Historically only about 14% of comparably fast-growing companies sustained such a pace across a ten-year window. The assumption is also unusually sensitive to the discount rate: each additional percentage point of required return shortens the tolerable horizon by roughly 2.7 years. A twenty-year runway of maximum growth is not a forecast anybody at the company has made. It is what the price arithmetic requires in order to make sense on the fundamentals alone.

The cash is real and the absence of borrowings genuinely removes one category of risk. But $1.0 billion against a $400 million annual burn is a finite thing, and its size is not the question. The question is what happens if the November decision goes the wrong way, because at that point the company would be funding an early pipeline out of a shrinking balance with a commercial base of roughly $20 million a quarter to show for it.

Valuation

Agios does not yet earn an operating profit, so the price has to be read against sales, and at that lens the number is stark: roughly thirty-eight times revenue. Inverting it produces a requirement that is specific rather than vague. The business would eventually need an operating margin near 35% and revenue growing at the maximum rate it can fund from its own resources, held for something in the region of twenty years. A 35% operating margin is achievable for a rare disease drug company; gross margin already runs near 88 cents on each revenue dollar, and the figure the price needs is essentially what survives of that after normal operating costs. The demanding part is not the margin. It is the duration.

How unusual that duration is has a measurable answer. Among comparably fast-growing companies, only about 14% sustained that kind of pace across a ten-year window. The calculation also carries an unusual sensitivity to the discount rate, with each percentage point of required return moving the tolerable horizon by about 2.7 years, which means a modest change in what investors demand from clinical-stage biotech rewrites the requirement substantially. Read plainly, the price is a bet that sits beyond what any conventional framework encodes.

The methods confirm that in an unusually uniform way. Not one family reaches today's price. The book-value approaches put it at roughly double what they support. The peer-multiple approach, which values the company on a sector sales multiple because there are no earnings to work with, lands many times below the price. The cash-flow approaches produce nothing at all, because they require positive cash flow and Agios currently consumes it, spending several times its revenue to run the business. When every frame lands under the price and one of them cannot compute an answer at all, the honest description is that the market is pricing an event that has not happened yet, and the frames are describing a company that has not happened yet either.

The event is dated. The FDA decision on mitapivat in sickle cell disease carries a goal date of November 1, 2026 under Priority Review. Sickle cell is a far larger population than the indications mitapivat currently serves, so the approval question sits directly under the revenue assumption the price contains. What the first quarter established is that the commercial machine works when it is given a label: U.S. net product revenue for mitapivat reached $18.8 million against $8.7 million a year earlier, on the strength of a thalassemia launch that was two months old.

The balance sheet sets the boundary rather than the value. Agios finished the first quarter with $1.0 billion in cash, cash equivalents and marketable securities and no funded borrowings, and the share count has risen only about 1.9% a year over four years, which is unusually little dilution for a company at this stage. At the current rate of spending, that balance buys years rather than quarters. It does not buy an approval.

Catalysts

The near-term calendar is unusually dense. Agios hosts its second quarter 2026 call on July 30, 2026 at 8 a.m. Eastern, which will give the first full quarter of AQVESME in thalassemia rather than the two-month stub the first quarter contained. The first quarter set the baseline at $20.7 million of total revenue, comprising $18.8 million of U.S. mitapivat product revenue and $1.9 million from outside the United States, against a net loss of $99.1 million. Prescription counts matter more than the revenue line this early in a launch, and 242 prescriptions had been written by certified physicians as of March 31, 2026.

The decisive event is November 1, 2026, the FDA goal date for the supplemental application seeking accelerated approval of mitapivat in sickle cell disease under Priority Review. The supporting Phase 3 data was presented at a plenary session of the European Hematology Association congress this year. Accelerated approval carries its own follow-on obligation, since confirmatory evidence has to arrive later, but the commercial effect of a label in sickle cell would be immediate.

The pipeline delivered a setback in July that is worth weighing against that. On July 21, 2026 the company reported that its Phase 2 trial of tebapivat in sickle cell disease did not show enough differentiation to justify continuing, and it discontinued the program. Hemoglobin response rates were consistent with the class and tolerability was in line with prior trials, so the failure was one of degree rather than of safety. What remains behind mitapivat is earlier: tebapivat continues in lower-risk myelodysplastic syndromes, alongside AG-181 in phenylketonuria and AG-236 in polycythemia vera. Each of those is a separate binary event on its own schedule.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• KMTS (Kestra Medical Technologies, Ltd.)
• FY2025 10-K: …an adhesive-based external defibrillator. As we continue to scale our business, our competitor may take competitive actions against us, including competitive pricing actions and litigation challenges, such as intellectual property challenges. In the future, we may also face competition from new market entrants. The…
• FY2025 10-K: …in the future that may adversely affect such policies and amounts. Changes in the healthcare industry directed at controlling healthcare costs or perceived over-utilization of cardiac monitoring products and services in ambulatory care environments could reduce the volume of demand for our products. If more…
• ZYME (ZYME)
• FY2025 10-K: …and new therapies that may become available in the future. With respect to our healthcare asset aggregation strategy, we face competition from other companies, funds and other investment vehicles seeking to aggregate royalties or provide alternative financing to biotechnology companies. These competitors may have a…
• FY2025 10-K: …foreign currencies will have an impact on the reported balances for net assets, net loss and stockholders' equity in the Company's consolidated financial statements. Segment Information The Company operates and manages its business in one segment, which is the Management of a portfolio of licensed healthcare assets…
• PTGX (PTGX)
• FY2025 10-K: …due to the intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other biopharmaceutical and pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different…
• FY2025 10-K: …of the marketing exclusivity period, even if we still have patent protection for such drugs. Competition that our product candidates, such as Icotyde and rusfertide, if approved, may face from generic drugs could materially and adversely impact our future revenue, profitability and cash flows and substantially limit…
• VRDN (Viridian Therapeutics, Inc.\DE)
• FY2025 10-K: …resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. For example, Amgen is a large biotechnology company in the competitive landscape for clinical trials and therapeutics for TED. Large…
• FY2025 10-K: …and the Company's tax returns are generally open under statute from 2020 to the present. Tax attributes such as net operating losses and tax credits generated prior to 2020 and utilized in open years may still be adjusted upon examination 16. SEGMENT INFORMATION The Company manages its operations as one operating…
• RXRX (RECURSION PHARMACEUTICALS, INC.)
• FY2025 10-K: …platform, pipeline, and business. Any drug candidates that we successfully develop and commercialize will compete with currently-approved therapies, and new therapies that may become available in the future, from segments of the pharmaceutical, biotechnology, and other related industries. The key competitive factors…
• FY2025 10-K: …and enforcing our intellectual property rights; and defending intellectual property-related claims of third parties; • our headcount growth and associated costs as we expand our business operations and our research and development activities, including into new geographies and through acquisitions; • the increase in…
• NTLA (NTLA)
• FY2025 10-K: …in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including promotion and marketing of…
• FY2025 10-K: …obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. In addition, our product candidates must be approved for marketing by the FDA, or certain other foreign regulatory…
• VIR (Vir Biotechnology, Inc.)
• FY2025 10-K: 028. In 2025, we entered into binding commitments with a CDMO for manufacture of our TCE products. As of December 31, 2025, we had unaccrued unpaid commitments of approximately $20 million for various TCE programs. Competition The pharmaceutical industry is characterized by rapidly advancing technologies, intense…
• FY2025 10-K: …and an emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Regulatory incentives to develop products for treatment of infectious…
• TNGX (TNGX)
• FY2025 10-K: …be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining…
• FY2025 10-K: …reimbursable cancer treatments. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach (as noted above), and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.